News

Atara Biotherapeutics Announces Pricing of Its Initial Public Offering

BRISBANE, Calif., Oct. 15, 2014 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts…
read more »

Atara Biotherapeutics Announces Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center

— T-cell Technology Harnesses Immune System to Fight Cancer and Infectious Disease — Brisbane, CA – [September 23, 2014] – Atara Biotherapeutics (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain…
read more »

Atara Biotherapeutics Strengthens Board; Senior Management Team

— Matthew K. Fust joins Board of Directors — — Mitchall G. Clark named Chief Regulatory and Quality Assurance Officer — BRISBANE and THOUSAND OAKS, Calif., April 8, 2014 – Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has strengthened its…
read more »

Atara Biotherapeutics Announces Second Closing of $52 Million Series B Financing

— Management to Present at the 32nd Annual J.P. Morgan Healthcare Conference —  BRISBANE, Calif. and THOUSAND OAKS, Calif., January 10, 2013 – Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today a second closing of its recently announced Series B financing, bringing the…
read more »

Atara Biotherapeutics Secures $38.5 Million Series B Financing

— Accelerates Two Development-Stage Compounds — — Appoints Joel Marcus as New Board Member — BRISBANE, Calif. and THOUSAND OAKS, Calif., December 17, 2013 – Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under…
read more »

Research Findings Presented at 2013 ASCO Annual Meeting

A team of oncology researchers including Dr. Christopher Haqq, Atara Biotherapeutics’ Chief Medical Officer, presented a poster at the June 2013 annual meeting of the American Society of Clinical Oncology in Chicago. The findings were published in the Journal of Clinical Oncology: “Effects of a soluble activin type 2B receptor Fc fusion protein (STM 217)…
read more »

Amgen and KPCB Partner to Create Atara Biotherapeutics

AMGEN AND KLEINER PERKINS CAUFIELD & BYERS PARTNER TO CREATE NEW SPIN-OUT BIOTECH COMPANY Amgen to License Pipeline Assets to Newly Formed Company THOUSAND OAKS, Calif. and MENLO PARK, Calif. (Oct. 25, 2012) – Amgen and Kleiner Perkins Caufield & Byers (KPCB) today announced the formation of Atara Biotherapeutics, (www.atarabio.com), a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including…
read more »